Vecima and VECTOR TECH SOLUTIONS Secure Entra® DAA Launching Point with ASTA-NET in Poland
Vecima Networks Inc. (TSX: VCM) today announced that VECTOR TECH SOLUTIONS is deploying Vecima’s Entra® SC-1D Access Node and Entra® Access Controller (EAC) solutions for ASTA-NET, a telecommunications provider in Poland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509796116/en/
The collaboration underscores Vecima’s commitment to expanding its footprint in the European market, with VECTOR TECH SOLUTIONS providing local expertise as a Vecima reseller in Poland. The deployment for ASTA-NET gives the Polish internet and communications technology (ICT) integrator an instant customer success story as it introduces Vecima’s innovative Remote MACPHY Device (RMD) Distributed Access Architecture (DAA) node to the Poland market.
The SC-1D, a cornerstone of the Entra family, is designed to enable operators like ASTA-NET to transition toward a more distributed, efficient, and scalable architecture. The SC-1D simplifies network design and enhances operational efficiency by moving PHY layer functions closer to the network edge, thereby reducing latency and increasing bandwidth availability.
Complementing the SC-1D, Vecima’s Entra Access Controller (EAC) serves as a centralized management platform that orchestrates the complex interactions between the core network and distributed access devices. The EAC ensures seamless integration and optimal performance of the DAA ecosystem, facilitating advanced features such as dynamic bandwidth allocation and network virtualization.
ASTA-NET’s adoption of Vecima’s technology through VECTOR TECH SOLUTIONS represents a pivotal step in enhancing its network infrastructure to deliver superior broadband services. With the Entra SC 1-D and EAC, ASTA-NET can position itself at the forefront of digital transformation.
“Collaboration with global broadband technology providers such as Vecima is a great honor,” said Artur Salwach, Sales Managing Director at VECTOR TECH SOLUTIONS. “We are glad we can cooperate with the world's leaders to provide solutions to Polish telecommunications operators such as ASTA-NET and develop their business.”
"Vecima and VECTOR TECH SOLUTIONS are closely aligned in our shared objective of advancing Poland's telecommunications sector," said German Iaryczower, Senior Vice President, Global Sales & Marketing at Vecima. "Our strategic partnership will continue to elevate and expand connectivity throughout Poland.”
For more information about Vecima’s Entra DAA platform, visit vecima.com/network-access/interoperable-daa-solutions.
About ASTA-NET
ASTA-NET, a company of the ASTA Group, present on the market since 1989, a leader in providing telecommunications services in northern Greater Poland and neighboring areas of the West Pomeranian Voivodeship. ASTA-NET covers over 140,000 households and provides services to over 63,000 individual and business clients. Its success is based on bold and permanent investments in network development and product development. The treasure of ASTA-NET is its qualified staff - technology enthusiasts and people focused on customer needs. The company's goal is to be the operator of first choice, i.e. the most desirable provider of multimedia services.
About VECTOR TECH SOLUTIONS
Polish integrator that designs and implements modern ICT solutions, responding to the growing market needs. VECTOR TECH SOLUTIONS supports organizations from various industries, guaranteeing high quality services in the field of optical technologies, uninterrupted power supply, cybersecurity, IT infrastructure and IP networks. The basis for the provided services is a good understanding of clients' business and certified technological knowledge. Everything they have learned over many years while conducting large and complex projects helps adapt their solutions to various and multi-faceted business challenges. Learn more at vectortechsolutions.com.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509796116/en/
Contact information
Investor Relations: 250-881-1982, invest@vecima.com
Media Relations: bernadette.dunn@vecima.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline4.9.2025 08:00:00 EEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB. Validation of Leadership Position in Microbiome-Based Therapeutics Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical da
Abbove Unveils “Mia”: Opening a New Chapter in Digital Wealth Planning in Europe4.9.2025 07:00:00 EEST | Press release
Abbove, the European platform for collaborative and family-centered wealth planning, announces today the launch of Mia, its new artificial intelligence agent. Used by more than 1,100 advisors and deployed to over 37,000 families across Europe, Abbove takes a major step forward in its mission to reimagine the wealth advisory experience in the digital age. Designed to enhance the capabilities of wealth advisors, family officers, and financial experts, Mia acts as an intelligent co-pilot. It simplifies the reading and analysis of complex estate documents, automatically extracts key information, and assists users in the understanding, enrichment, and structuring of wealth data. “The launch of Mia opens an entirely new functional AI vertical on our platform, unlocking near-infinite possibilities for future development. It’s a key milestone that brings us closer to our ambition of becoming the leading pan-European wealth planning platform.” — Guillaume Desclée, Founder & CEO of Abbove Native
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions4.9.2025 03:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/ Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and su
OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 20:23:00 EEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 19:19:00 EEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom